The paradox of dysfunctional high-density lipoprotein

Current Opinion in Lipidology

Volumn 18, Issue 4, 2007, Pages 427-434

  Ansell, Benjamin J ^a,b   Fonarow, Gregg C ^a   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoprotein A I; Apolipoprotein mimetic peptides; HDL; Inflammation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN D; APOLIPOPROTEIN D[113-122]; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PREDNISOLONE; SIMVASTATIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIAC GRAFT REJECTION; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIET; DRUG EFFECT; DRUG TARGETING; EXERCISE; GENE EXPRESSION; GENETIC ANALYSIS; GLYCATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPID COMPOSITION; LIPID OXIDATION; LIPID TRANSPORT; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULITIS;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPIDS; LIPOPROTEINS, HDL; MODELS, BIOLOGICAL; MODELS, GENETIC; RISK;

EID: 34447341178     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282364a17     Document Type: Review

References (62)

1. Pearson H. When good cholesterol turns bad. Nature 2006; 444:794-795.
2. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007; 27:257-260. This article presents arguments supporting both molecule-specific toxicity of torcetrapib as well as CETP inhibition as potential causes of the drug's failure.
3. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep 2006; 8:405-411.
4. Negre-Salvayre A, Dousset N, Ferretti G, et al. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006; 41:1031-1040.
5. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89:10316-10320.
6. Brewer HB Jr. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004; 24:387-391.
7. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004; 95:764-772.
8. Baldan A, Tarr P, Lee R, Edwards PA. ATP-binding cassette transporter G1 and lipid homeostasis. Curr Opin Lipidol 2006; 17:227-232.
9. Subbanagounder G, Leitinger N, Schwenke DC, et al. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol 2000; 20:2248-2254.
10. Fogelman AM. When pouring water on the fire makes it burn brighter. Cell Metab 2005; 2:6-8.
11. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88:2039-2046.
12. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924.
13. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79:319-326.
14. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41:1481-1494.
15. Miyazaki A, Rahim AT, Ohta T, et al. High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells. Biochim Biophys Acta 1992; 1126:73-80.
16. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41:1495-1508.
17. Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42:1308-1317.
18. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006; 48:715-720. This study demonstrates the impact of dietary fat composition on regulation by HDL of cellular adhesion molecule expression.
19. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108:2751-2756.
20. Navab M, Anantharamaiah GM, Reddy ST, et al. The double jeopardy of HDL. Ann Med 2005; 37:1-6.
21. Barter P. The inflammation: lipoprotein cycle. Atheroscler Suppl 2005; 6:15-20.
22. Baker PW, Rye KA, Gamble JR, et al. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res 2000; 41:1261-1267.
23. Watson KE, Hama S, Fonarow GC, et al. Metabolic syndrome patients have higher plasma lipid hydroperoxides and more pro-inflammatory HDL than dyslipidemic control subjects, even with comparable levels of HDL, hs-CRP and paraoxonase activity. Circulation 2004; 110:III-52.
24. Kaysen GA. Disorders in high-density metabolism with insulin resistance and chronic kidney disease. J Ren Nutr 2007; 17:4-8.
25. Tan KCB, Chow W-S, Lam JCM, et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006; 184:377-382.
26. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96:2758-2767.
27. McMahon M, Grossman J, Fitzgerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:2541-2549. This important study characterizes the frequency of proinflammatory HDL in lupus and rheumatoid arthritis.
28. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999; 19:2226-2233.
29. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89:4963-4971.
30. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001; 103:2283-2288.
31. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351:2611-2618.
32. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145:408-415.
33. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52:722-732.
34. Sviridov D, Chin-Dusting J, Nestel P, et al. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation 2006; 81:361-366. This article outlines structural and functional changes in HDL in solid organ transplantation that could contribute to transplant atherosclerosis.
35. Jensen-Urstad K, Johansson J, Jensen-Urstad M. Vascular function correlates with risk factors for cardiovascular disease in a healthy population of 35-year-old subjects. J Intern Med 1997; 241:507-513.
36. Yamashita S, Maruyama T, Hirano K-I, et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis 2000; 152:271-285.
37. Kontush A, de Faria EC, Chantepie S, Chapman MJ. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004; 24:526-533.
38. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43:312-320.
39. Ferretti G, Bacchetti T, Marchionni C, et al. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38:163-169.
40. Ferretti G, Bacchetti T, Negre-Salvayre A, et al. Structural modifications of HDL and functional consequences. Atherosclerosis 2006; 184:1-7. This is the most complete review of known structural changes within HDL that can have an impact specific atheroprotective functions.
41. Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004; 15:269-278.
42. Nicholls SJ, Zheng L, Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 2005; 15:212-219.
43. Ishimoto Y, Yamada K, Yamamoto S, et al. Group V and X secretory phospholipase A2s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim Biophys Acta 2003; 1642:129-138.
44. Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase Cdelta pathway. J Lipid Res 2007.
45. Bostrom MA, Boyanovsky BB, Jordan CT, et al. Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007; 27:600-606.
46. Callegari E, Norata GD, Inoue H, Catapano AL. Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. Int J Mol Med 2006; 18:209-213.
47. Norata GD, Banfi C, Pirillo A, et al. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. Br J Haematol 2004; 127:97-104.
48. Norata GD, Pellegatta F, Hamsten A, et al. Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. Int J Mol Med 2003; 12:73-78.
49. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant: the Limone sul Garda Study. Circulation 2001; 103:1949-1954.
50. Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999; 19:378-383.
51. Singaraja RR, Brunham LR, Visscher H, et al. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol 2003; 23:1322-1332.
52. Sviridov D, Nestel PJ. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007; 18:157-163.
53. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 2006; 47:2492-2502.
54. Baum L, Ng HK, Woo KS, et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 2006; 39:191-195.
55. Ranade K, Kirchgessner TG, Iakoubova OA, et al. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005; 36:2346-2350.
56. Tripi LM, Manzi S, Chen Q, et al. Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 2006; 54:1928-1939.
57. Charles-Schoeman C, Khanna D, Furst DE, et al. Effects of high-dose atorvastatin on HDL anti-inflammatory/pro-inflammatory function and disease activity in patients with rheumatoid arthritis. Results of the Statin Anti-Rheumatic Activity (SARA) pilot study. J Rheumatol 2007 (in press).
58. Roberts CK, Ng C, Hama S, et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/ obese men with cardiovascular risk factors. J Appl Physiol 2006; 101:1727-1732. This study illustrates the effects of therapeutic lifestyle changes on HDL dysfunction in the setting of metabolic syndrome.
59. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of prebeta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109:3215-3220.
60. Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45:993-1007.
61. Dunbar RL, Bloedon LT, Duffy D, et al. Daily oral administration of the apolipoprotein A-I mimetic peptide D-4F in patients with coronary heart disease or equivalent risk improves high-density lipoprotein anti-inflammatory function [abstract]. In: American College of Cardiology 56th Annual Scientific Session; 24-27 March 2007; New Orleans, LA. American College of Cardiology 2007. http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp? AKey=7455dae5-72d2-487b-a9ca-c5758f04c24e&mKey=0E7F77D6-3174-40F2-A276- 924B4A5A6579&SKey=7584a015-3d8a-4e01-8b2e-4103bee17882&CKey= a2176c3c-7749-41a0-9363-0341c1b57b69 [Last accessed 17 May 2007].
62. Navab M, Anantharamaiah GM, Reddy ST, et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25:1932-1937.